Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease

Brain Research

Volumn 1249, Issue , 2009, Pages 1-8

  Zuo, Xiumei ^a,b   Jia, Jianping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Alzheimer's disease; IDE; Polymorphism; Promoter

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; INSULINASE; LUCIFERASE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASE SEQUENCE; CELLS, CULTURED; FEMALE; HAPLOTYPES; HELA CELLS; HUMANS; INSULYSIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 58149170562     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.10.034     Document Type: Article

References (47)

1. Abraham R., Myers A., Wavrant-DeVrieze F., Hamshere M.L., Thomas H.V., Marshall H., Compton D., Spurlock G., Turic D., Hoogendoorn B., Kwon J.M., Petersen R.C., Tangalos E., Norton J., Morris J.C., Bullock R., Liolitsa D., Lovestone S., Hardy J., Goate A., O, Donovan M., Williams J., Owen M.J., and Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum. Genet. 109 (2001) 646-652
2. Bian L., Yang J.D., Guo T.W., Sun Y., Duan S.W., Chen W.Y., Pan Y.X., Feng G.Y., and He L. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology 63 (2004) 241-245
3. Bennett R.G., Duckworth W.C., and Hamel F.G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275 (2000) 36621-36625
4. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., McInnis M.G., Go R.C., Vekrellis K., Selkoe D.J., Saunders A.J., and Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290 (2000) 2302-2303
5. Boussaha M., Hannequin D., Verpillat P., Brice A., Frebourg T., and Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci. Lett. 329 (2002) 121-123
6. Cellini E., Bagnoli S., Tedde A., Nacmias B., Piacentini S., and Sorbi S. Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19 (2005) 246-247
7. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., and Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 162 (2003) 313-319
8. Dewji N.N., Do C., and Bayney R.M. Transcriptional activation of Alzheimer's beta-amyloid precursor protein gene by stress. Brain Res. Mol. Brain Res. 33 (1995) 245-253
9. Edland S.D. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 213-217
10. Edland S.D., Wavrant-DeVriesé F., Compton D., Smith G.E., Ivnik R., Boeve B.F., Tangalos E.G., and Petersen R.C. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci. Lett. 345 (2003) 21-24
11. Ertekin-Taner N., Allen M., Fadale D., Scanlin L., Younkin L., Petersen R.C., Graff-Radford N., and Younkin S.G. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum. Mutat. 23 (2004) 334-342
12. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4162-4167
13. Farris W., Mansourian S., Leissring M.A., Eckman E.A., Bertram L., Eckman C.B., Tanzi R.E., and Selkoe D.J. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am. J. Pathol. 164 (2004) 1425-1434
14. Feuk L., McCarthy S., Andersson B., Prince J.A., and Brookes A.J. Mutation screening of a haplotype block around the insulin degrading enzyme gene and association with Alzheimer's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 136 (2005) 69-71
15. Heijmans B.T., Slagboom P.E., Gussekloo J., Droog S., Lagaay A.M., Kluft C., Knook D.L., and Westendorp R.G. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am. J. Med. Genet. 107 (2002) 201-208
16. Hoyer A., Bardenheuer H.J., Martin E., and Plaschke K. Amyloid precursor protein (APP) and its derivatives change after cellular energy depletion. An in vitro-study. J. Neural. Transm. 112 (2005) 239-253
17. Kirschner R.J., and Goldberg A.L. A high molecular weight metalloendoprotease from the cytosol of mammalian cells. J. Biol. Chem. 258 (1983) 967-976
18. Kuo W.L., Montag A.G., and Rosner M.R. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology 132 (1993) 604-611
19. Kurochkin I.V., and Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS. Lett. 345 (1994) 33-37
20. Kurochkin I.V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26 (2001) 421-425
21. Lahiri D.K., Ghosh C., and Ge Y.W. A proximal gene promoter region for the beta-amyloid precursor protein provides a link between development, apoptosis, and Alzheimer's disease. Ann. N. Y. Acad. Sci. 1010 (2003) 643-647
22. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., and Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
23. Ling Y., Morgan K., and Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int. J. Biochem. Cell Biol. 35 (2003) 1505-1535
24. Lv H., Jia L., and Jia J. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Neurobiol. Aging 29 (2008) 194-202
25. McDermott J.R., and Gibson A.M. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. 22 (1997) 49-56
26. Miller B.C., Eckman E.A., Sambamurti K., Dobbs N., Chow K.M., Eckman C.B., Hersh L.B., and Thiele D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6221-6226
27. Misbin R.I., and Almira E.C. Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14-and B26-[125I] monoiodoinsulin. Diabetes 38 (1989) 152-158
28. Mukherjee A., Song E., Kihiko-Ehmann M., Goodman J.P.J., Pyrek J.S., Estus S., and Hersh L.B. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J. Neurosci. 20 (2000) 8745-8749
29. Myers A.J., and Goate A.M. The genetics of late-onset Alzheimer's disease. Curr. Opin. Neurol. 14 (2001) 433-440
30. Nowotny P., Hinrichs A.L., Smemo S., Kauwe J.S., Maxwell T., Holmans P., Hamshere M., Turic D., Jehu L., Hollingworth P., Moore P., Bryden L., Myers A., Doil L.M., Tacey K.M., Gibson A.M., McKeith I.G., Perry R.H., Morris C.M., Thal L., Morris J.C., O, Donovan M.C., Lovestone S., Grupe A., Hardy J., Owen M.J., Williams J., and Goate A. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 136 (2005) 62-68
31. Ogawa W., Shii K., Yonezawa K., Baba S., and Yokono K. Affinity purification of insulin-degrading enzyme and its endogenous inhibitor from rat liver. J. Biol. Chem. 267 (1992) 1310-1316
32. Pérez A., Morelli L., Cresto J.C., and Castaño E.M. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 25 (2000) 247-255
33. Prince J.A., Feuk L., Gu H.F., Johansson B., Gatz M., Blennow K., and Brookes A.J. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum. Mutat. 22 (2003) 363-371
34. Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006) 190-198
35. Qiu W.Q., Ye Z., Kholodenko D., Seubert P., and Selkoe D.J. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272 (1997) 6641-6646
36. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
37. Olsson A., Csajbok L., Ost M., Höglund K., Nylén K., Rosengren L., Nellgård B., and Blennow K. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J. Neurol. 251 (2004) 870-876
38. Sakai A., Ujike H., Nakata K., Takehisa Y., Imamura T., Uchida N., Kanzaki A., Yamamoto M., Fujisawa Y., Okumura K., and Kuroda S. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 125 (2004) 87-91
39. Sander P., Hamann H., Drögemüller C., Kashkevich K., Schiebel K., and Leeb T. Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility. J. Biol. Chem. 280 (2005) 37408-37414
40. Sudoh S., Frosch M.P., and Wolf B.A. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and-insoluble pools in CHO-695 cells. Biochemistry 41 (2002) 1091-1099
41. Tabner B.J., El-Agnaf O.M., Turnbull S., German M.J., Paleologou K.E., Hayashi Y., Cooper L.J., Fullwood N.J., and Allsop D. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J. Biol. Chem. 280 (2005) 35789-35792
42. Tanzi R.E., and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32 (2001) 181-184
43. Tsai M.S., Tangalos E.G., Petersen R.C., Smith G.E., Schaid D.J., Kokmen E., Ivnik R.J., and Thibodeau S.N. Apolipoprotein E: risk factor for Alzheimer disease. Am. J. Hum. Genet. 54 (1994) 643-649
44. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., and Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000) 1657-1665
45. Vepsäläinen S., Parkinson M., Helisalmi S., Mannermaa A., Soininen H., Tanzi R.E., Bertram L., and Hiltunen M. Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J. Med. Genet. 44 (2007) 606-608
46. Yan H., Yuan W., Velculescu V.E., Vogelstein B., and Kinzler K.W. Allelic variation in human gene expression. Science 297 (2002) 1143
47. Zhang X.Q., and Eyzaguirre C. Effects of hypoxia induced by Na2S2O4 on intracellular calcium and resting potential of mouse glomus cells. Brain Res. 818 (1999) 118-126